Working… Menu

A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01721148
Recruitment Status : Completed
First Posted : November 5, 2012
Last Update Posted : January 25, 2017
Information provided by (Responsible Party):
Aslan Pharmaceuticals